Combination Study of Antibiotics With Enzalutamide (PROMIZE)
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the
safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide
in patients with metastatic castration-resistant prostate cancer (mCRPC).